These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12495359)

  • 1. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.
    Berry DC; Raynor DK; Knapp P; Bersellini E
    Drug Saf; 2003; 26(1):1-11. PubMed ID: 12495359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two methods of presenting risk information to patients about the side effects of medicines.
    Knapp P; Raynor DK; Berry DC
    Qual Saf Health Care; 2004 Jun; 13(3):176-80. PubMed ID: 15175486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. People's Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England.
    Webster RK; Weinman J; Rubin GJ
    Drug Saf; 2017 Aug; 40(8):743-754. PubMed ID: 28497250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communicating the risk of side effects to patients: an evaluation of UK regulatory recommendations.
    Knapp P; Raynor DK; Woolf E; Gardner PH; Carrigan N; McMillan B
    Drug Saf; 2009; 32(10):837-49. PubMed ID: 19722727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over the counter medicines and the need for immediate action: a further evaluation of European Commission recommended wordings for communicating risk.
    Berry D; Raynor T; Knapp P; Bersellini E
    Patient Educ Couns; 2004 May; 53(2):129-34. PubMed ID: 15140451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adequacy of patient information on adverse effects: an assessment of patient information leaflets in the UK.
    Carrigan N; Raynor DK; Knapp P
    Drug Saf; 2008; 31(4):305-12. PubMed ID: 18366241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Side Effect Risk Communication in Patient Information Leaflets over the Past Decade: Results of a Survey.
    Harris K; Dickinson R; Raynor DK; MacDonald J; Knapp P
    Drug Saf; 2015 Aug; 38(8):721-7. PubMed ID: 26100144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined verbal and numerical expressions increase perceived risk of medicine side-effects: a randomized controlled trial of EMA recommendations.
    Knapp P; Gardner PH; Woolf E
    Health Expect; 2016 Apr; 19(2):264-74. PubMed ID: 25645270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' preferences shed light on the murky world of guideline-based medicine.
    Penston J
    J Eval Clin Pract; 2007 Feb; 13(1):154-9. PubMed ID: 17286739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verbal descriptors of the frequency of side effects: implementation of EMA recommendations in patient information leaflets in Poland.
    Olchowska-Kotala A; Uchmanowicz I; Szczepanowski R
    Int J Qual Health Care; 2022 Mar; 34(1):. PubMed ID: 35277713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceived risk of tamoxifen side effects: a study of the use of absolute frequencies or frequency bands, with or without verbal descriptors.
    Knapp P; Gardner PH; Raynor DK; Woolf E; McMillan B
    Patient Educ Couns; 2010 May; 79(2):267-71. PubMed ID: 19896321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceived risk of medicine side effects in users of a patient information website: a study of the use of verbal descriptors, percentages and natural frequencies.
    Knapp P; Gardner PH; Carrigan N; Raynor DK; Woolf E
    Br J Health Psychol; 2009 Sep; 14(Pt 3):579-94. PubMed ID: 18992183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving communication of drug risks to prevent patient injury: proceedings of a workshop.
    Campbell WH; Califf RM
    Pharmacoepidemiol Drug Saf; 2003; 12(3):183-94. PubMed ID: 12733471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk communication in clinical trials: a cognitive experiment and a survey.
    Cheung YB; Wee HL; Thumboo J; Goh C; Pietrobon R; Toh HC; Yong YF; Tan SB
    BMC Med Inform Decis Mak; 2010 Sep; 10():55. PubMed ID: 20868525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk/Benefit Communication: International Developments and Prospects for the Future].
    Yamamoto M
    Yakugaku Zasshi; 2018; 138(3):299-306. PubMed ID: 29503420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
    Lorimer S; Cox A; Langford NJ
    J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.